VitroScan - Predicting Treatment OutcomeVitroScan B.V. is a Dutch biotech company established in 2016 and based at the Leiden Bio Science Park. We focus on the development of predictive tumor testing services to support better informed treatment decisions for cancer patients.

VitroScan - Predicting Treatment OutcomeVitroScan B.V. is a Dutch biotech company established in 2016 and based at the Leiden Bio Science Park. We focus on the development of predictive tumor testing services to support better informed treatment decisions for cancer patients. Cancer is a leading cause of death worldwide and this will only rise in ageing populations. Development of effective treatment, and identification of the patients that benefit from it remains a big challenge. High failure rates in clinical development, suboptimal treatment efficacy, unnecessary side effects, and difficulty to motivate associated cost for (novel) drug treatment while the burden for the health care system is widely debated.VitroScan is dedicated to deliver predictive testing services to clinicians world wide to support better informed treatment decisions for cancer patients. Technology:VitroScans' Best in Class technology has developed an ex vivo 3D tumor testing platform. The strength of our technology is the extensive expertise in 3D tumor testing, imaging to measure and quantify drug effects in detail, and advanced bio informatics using AI based algorithms to classify the patients tumor sensitivity to drugs. Pipeline: VitroScan is running a clinical trial program to establish the predictive value of our ex vivo tumor testing platform for several tumor types, including ovarian cancer, and mesothelioma in collaboration with (academic) hospitals in the EU.

Responsible for the Sanofi Genzyme hemato-oncology portfolio: Mozobil, Evoltra, Fasturtec en pre-launch activities for JAK-2 inhibitor and anti-CD38 for the indications multiple myeloma, lymphoma, stem cell transplantation, pediatric hemato-oncology and myelofibrosis. Main activities include strategic and operational planning for products in line with EU and global brand teams. Key opinion leader management niche markets. Optimization of treatment effectiveness by innovative contracting (pay for performance, consignment) in collaboration with market access, finance, and external stakeholders. Responsible for budget planning, brand teams, advisory boards, development of sales aids. Close collaboration with department of clinical research for early development of new hemato-oncology molecules.

From April 2011 until March 2013 Sanofi acquired distribution rights for MammaPrint. Preceding the deal responsibility for identification of the business opportunity, building the business case in collaboration with business development, market research, and preparation of the practical implications and logistics of distribution of this diagnostic product by Sanofi. Next as a Brand Manager responsible for launch, marketing, and distribution of MammaPrint. Activities comprised market research, key opinion leader management, strategic and operational planning, budget, develop detail material, chair brand team, prepare and give medical/marketing training, setup customer service, respond to patients questions, communicate to patients (www.mammprint.nl), support reimbursement process (CVZ and individual HIC’s) in close collaboration with market access.

Responsible for investigator initiated studies in oncology (taxotere) as a member of oncology brand team. Principally breast cancer, and ovary cancer. Activities comprised monitoring of study progress and deadlines, budget planning, negotiation of contracts, review publications, KOL management, and intensive collaboration with research working groups (BOOG, CPCT, NKI-AvL, MUMC, UMCG, Radboud UMC) in line with strategic planning for products, within the legal context and with scientific publications as major goal.‘National Sales Champion’ nominated in '07, '08, '09, winner in '08, and '09.

Coordination of various clinical trials (phase II, III), submission METC,site selection, initiation, monitoring, audits, relation management with medical doctors. Primarily in indications: cardiology, internal medicine, hematology, endocrinology,

PhD, Department Immuno-hematology and blood transfusion, LUMC. Thesis: Coeliac Disease-Across the threshold of tolerance.Graduated: Cum Laude, March 2003Faculteit: GeneeskundePromotor: prof. dr. R.R.P. de VriesCo-promotor: prof. dr. F. KoningResearch of the causes and development of Celiac Disease. Result: Opportunities for disease prevention in young children.‘Young Investigators Award’, 9th international conference on celiac disease, Baltimore, August 2000.